Voya Investment Management LLC Has $15.35 Million Position in MoonLake Immunotherapeutics $MLTX

Key Points

• Voya Investment Management LLC has reduced its stake in MoonLake Immunotherapeutics by 12.5%, selling 55,936 shares during the first quarter.
• Deutsche Bank AG has increased its position in MoonLake Immunotherapeutics by 59.8%, indicating a growing interest from institutional investors.
• Analysts have a consensus rating of "Moderate Buy" for the stock, with a price target averaging $74.43 per share.

Voya Investment Management LLC lowered its position in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 12.5% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 392,924 shares of the company's stock after selling 55,936 shares during the quarter. Voya Investment Management LLC owned about 0.61% of MoonLake Immunotherapeutics worth $15,352,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Deutsche Bank AG grew its position in MoonLake Immunotherapeutics by 59.8% in the fourth quarter. Deutsche Bank AG now owns 903 shares of the company's stock valued at $49,000 after acquiring an additional 338 shares during the last quarter. US Bancorp DE raised its position in shares of MoonLake Immunotherapeutics by 114.4% during the first quarter. US Bancorp DE now owns 2,208 shares of the company's stock worth $86,000 after purchasing an additional 1,178 shares during the period. Quarry LP acquired a new position in shares of MoonLake Immunotherapeutics during the first quarter worth approximately $94,000. Advisors Asset Management Inc. grew its holdings in MoonLake Immunotherapeutics by 81.7% during the first quarter. Advisors Asset Management Inc. now owns 4,009 shares of the company's stock worth $157,000 after buying an additional 1,803 shares in the last quarter. Finally, Legato Capital Management LLC bought a new position in MoonLake Immunotherapeutics in the 1st quarter valued at $240,000. Institutional investors own 93.85% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on MLTX shares. Redburn Atlantic raised MoonLake Immunotherapeutics to a "hold" rating in a report on Monday, July 28th. Rothschild & Co Redburn assumed coverage on MoonLake Immunotherapeutics in a report on Monday, July 28th. They issued a "neutral" rating and a $65.00 target price on the stock. Royal Bank Of Canada reiterated an "outperform" rating and set a $67.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Tuesday, June 3rd. Finally, The Goldman Sachs Group upped their price objective on MoonLake Immunotherapeutics from $74.00 to $82.00 and gave the stock a "buy" rating in a research note on Wednesday, August 6th. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $74.43.

MoonLake Immunotherapeutics Stock Performance

MoonLake Immunotherapeutics stock traded down $0.38 during trading hours on Friday, hitting $53.78. 649,035 shares of the stock traded hands, compared to its average volume of 740,562. The stock has a market capitalization of $3.45 billion, a price-to-earnings ratio of -19.35 and a beta of 1.27. The firm's 50 day moving average price is $54.29 and its 200-day moving average price is $45.53. The company has a debt-to-equity ratio of 0.21, a current ratio of 16.65 and a quick ratio of 16.65. MoonLake Immunotherapeutics has a 1 year low of $31.42 and a 1 year high of $61.87.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.87) earnings per share for the quarter, missing analysts' consensus estimates of ($0.73) by ($0.14). During the same period in the prior year, the business earned ($0.39) earnings per share. As a group, equities analysts expect that MoonLake Immunotherapeutics will post -1.79 EPS for the current fiscal year.

MoonLake Immunotherapeutics Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.